The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.NEW YORK ( Insider Monkey) -- Academic research has shown that insider purchases on average outperformed the market over the following 12-month period. On the other hand, insider sales are usually not informative. This is because most insider sales are motivated by diversification or liquidity needs. Therefore, insider sales really do not mean much compared with insider purchases. However, recent research on insider sales has shown that stocks sold under the 10b5-1 plans have large negative abnormal returns. The magnitude of the abnormal returns is about 70 basis points per month calculated by using Carhart's four factor model. In this article, we are going to discuss a few large-cap stocks that insiders are selling like crazy under 10b5-1 plans in the past week. All companies have at least $5 billion market cap. Follow TheStreet on Twitter and become a fan on Facebook.
Overall, I wouldn't sell Broadcom because of the recent insider sales. However, I wouldn't buy the stock because of the mobile revolution. I'd rather buy Apple. Edwards Lifesciences ( EW): Similar to BRCM, EW was also sold by four insiders under the 10b5-1 plans in February. On Feb. 6, Michael Mussallem sold 35,000 shares at about $71 per share. Huimin Wang also sold 10,240 shares at prices ranging from $70.76 to $72.45 on the same day. John Kehl sold 15,000 shares at around $81 per share on February 2, and Patrick Verguet sold 6,000 shares at $82.67 at the beginning of February. Mussallem, Wang, Kehl, Verguet and three other insiders also sold a large amount of EW shares in January. Now EW is trading at $73.67 per share. EW's current price is much lower than its price at the beginning of February, but it is still higher than the prices Mussallem and Wang sold at. We recommend investors to be careful about this stock. The medical equipment and supplies industry is highly competitive. The company is faced with the threat from not only existing competitors, but also new entrants to the market. In order to maintain its competitive strength, EW has to keep developing new products and improving old ones. Edwards Lifesciences is expect to earn about $2.75 per share in 2012 and $3.50 in 2013. Its trailing P/E ratio is 37. If everything goes according to plan, its 2013 forward P/E ratio is 21. This is quite rich for a value investor like us. By way of comparison, Apple is growing like a weed, but Apple's 2013 forward P/E ratio is in single digits. We wouldn't buy Edwards Lifesciences at these prices. We actually think the stock is likely to underperform the market over the long-term. Some of the prominent hedge funds like Jim Simons' Renaissance Technologies and Steven Cohen's SAC Capital Advisors sold out their EW stakes over the third quarter. Rackspace Hosting ( RAX): RAX was sold by four insiders in February. James Bishkin sold 4,600 shares at $48.2728 on Feb. 6. Bishkin also sold 2,500 shares at $46.0088 on Feb. 3. Another insider, Lew Moorman sold 11,750 shares of RAX at $42.4273 and another 63,000 shares at $47.4273 on Feb. 3. Moorman also sold 2,250 shares of RAX at $44.084 two days earlier. Patrick Matthews also sold 5,000 shares at $43.5743 on Feb. 3 and another 5,000 shares at $43.9981 on Feb. 1. And Wayne Phillip Roberts sold 4,000 shares at $44.0013 at the beginning of February.
Today RAX is trading at $49.62 per share, even higher than the prices these insiders sold at. However, we do not like RAX. It has an extremely high P/E ratio of 105.57 and a high forward P/E ratio of 61.26. Its other multiples, such as PEG, P/B, and P/FCF, are also not attractive. Its expected EPS growth rate over the next five years is similar to Edwards Lifesciences but its P/E ratio is almost three times higher. If we were managing a long/short portfolio, RAX would have been one of the stocks we short. Over the third quarter, Cliff Asness' AQR Capital Management and Israel Englander's Millennium Management both sold out their RAX stakes. A few other large-cap stocks that insiders are selling under 10b5-1 plans are Equinix ( EQIX), Tractor Supply Company ( TSCO), and Ashland ( ASH). But their insider sales are much smaller compared with the three stocks we discussed above. They were also only sold by one insider in February, versus four insiders for RAX, EW, and BRCM. Therefore, we think the insiders sales signals for EQIX, TSCO and ASH aren't significant enough for a closer look. But we will be tracking these stocks closely and report additional insider sales by the same insiders or other insiders.